Loading...
SQZB logo

SQZ Biotechnologies CompanyOTCPK:SQZB Stock Report

Market Cap US$707.8k
Share Price
US$0.024
My Fair Value
n/a
1Y-14.3%
7D0%
1D
Portfolio Value
​
View

SQZ Biotechnologies Company

OTCPK:SQZB Stock Report

Market Cap: US$707.8k

SQZ Biotechnologies (SQZB) Stock Overview

A clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. More details

SQZB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($708K)

Latest financial reports are more than a year old


SQZB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

SQZ Biotechnologies Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for SQZ Biotechnologies
Historical stock prices
Current Share PriceUS$0.024
52 Week HighUS$0.05
52 Week LowUS$0.023
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change-14.29%
3 Year Change-93.33%
5 Year Change-99.83%
Change since IPO-99.82%

Recent News & Updates

Analysis Article • Jun 26

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders that were waiting for something to happen have been dealt a blow...

Recent updates

Analysis Article • Jun 26

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Jan 05

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 09

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

SQZ Biotechnologies press release (NYSE:SQZ): Q3 GAAP EPS of -$0.77 beats by $0.06. Revenue of $3.5M (-27.1% Y/Y) misses by $0.76M. Company had cash and cash equivalents of $84.2 million and anticipates this will be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2023
Seeking Alpha • Oct 20

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

SQZ Biotechnologies (NYSE:SQZ), a biotech focused on cell therapies, added ~5% pre-market Thursday after H.C. Wainwright launched its coverage with a Buy rating and a $5 target highlighting the company’s Cell Squeeze technology platform. The analyst Emily Bodnar notes that the Cell Squeeze technology is designed to address many shortcomings in current cell therapy platforms as it doesn’t require lymphodepletion, allows flexibility of cell type and cargo, and faster production while maintaining cell health and function. The Antigen Presenting Cell (APC) platform, SQZ’s most advanced cell therapy technology is a collaboration with Roche (OTCQX:RHHBY) (OTCQX:RHHBF) which validates its potential, the analyst argued. Bodnar sees multiple catalysts ahead for SQZ before year-end as the company expects to report updated data for the APC program and initial data for eAPC and AAC programs in Q4 2022. Early this year, the FDA granted Fast Track designation for SQZ’s APC clinical candidate, SQZ-PBMC-HPV, for HPV16+ advanced or metastatic tumors.
Analysis Article • Aug 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

SQZ Biotechnologies press release (NYSE:SQZ): Q2 GAAP EPS of -$0.78 misses by $0.01. Revenue of $3.22M (-29.1% Y/Y) misses by $0.97M. “We are excited by meaningful progress in our clinical trials and also the receipt of FDA Fast Track Designation for our APC clinical candidate across HPV16+ tumors,” said Armon Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies. “We also highlighted the progress in developing our Point-of-Care manufacturing system which supports our long-term vision to enable broad accessibility of cell therapies. Finally, I am delighted by the addition of our newest senior team member, Dr. Marshelle Smith Warren as our Chief Medical Officer, and the elevation of Micah Zajic to Chief Financial Officer.”
Seeking Alpha • Jul 11

SQZ Biotechnologies names business chief as CFO

SQZ Biotechnologies (NYSE:SQZ) announced Monday the promotion of Micah Zajic to the role of company's chief financial officer, effective immediately. Zajic has served as the company’s chief business officer since October 2020 and brings nearly two decades of biotechnology and capital markets experience to the role. Prior to joining SQZ, he led corporate development activities at MeiraGTx Holdings including execution of a collaboration agreement with Janssen Pharmaceuticals. Earlier: SQZ Biotechnologies names Marshelle Smith Warren as chief medical officer
Analysis Article • May 17

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

Market forces rained on the parade of SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders today, when the analysts...
Analysis Article • May 02

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 11

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jul 30

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 16

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

SQZ Biotechnologies Company ( NYSE:SQZ ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Mar 25

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

The analysts covering SQZ Biotechnologies Company ( NYSE:SQZ ) delivered a dose of negativity to shareholders today, by...
Analysis Article • Mar 20

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

SQZ Biotechnologies Company ( NYSE:SQZ ) came out with its full-year results last week, and we wanted to see how the...
Analysis Article • Feb 01

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

SQZBUS BiotechsUS Market
7D0%2.8%-1.8%
1Y-14.3%35.2%23.3%

Return vs Industry: SQZB underperformed the US Biotechs industry which returned 31.4% over the past year.

Return vs Market: SQZB underperformed the US Market which returned 25.7% over the past year.

Price Volatility

Is SQZB's price volatile compared to industry and market?
SQZB volatility
SQZB Average Weekly Movement0.4%
Biotechs Industry Average Movement10.7%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SQZB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SQZB's weekly volatility has decreased from 10% to 0% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013n/an/awww.sqzbiotech.com

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.

SQZ Biotechnologies Company Fundamentals Summary

How do SQZ Biotechnologies's earnings and revenue compare to its market cap?
SQZB fundamental statistics
Market capUS$707.79k
Earnings (TTM)-US$71.64m
Revenue (TTM)US$12.12m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is SQZB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SQZB income statement (TTM)
RevenueUS$12.12m
Cost of RevenueUS$51.79m
Gross Profit-US$39.67m
Other ExpensesUS$31.97m
Earnings-US$71.64m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did SQZB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 06:14
End of Day Share Price 2026/06/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SQZ Biotechnologies Company is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Leah Rush CannBrookline Capital Markets
Thomas ShraderBTIG